Navigation Links
Isogenic cell models for cancer research exclusively licensed to Horizon Discovery

CLEVELAND With the goal of developing new, more effective and personalized cancer treatments, Horizon Discovery, based in Cambridge, England, has secured from Case Western Reserve University exclusive rights to a panel of new human isogenic cell models developed by the laboratory of Zhenghe John Wang, assistant professor of genetics at the university's School of Medicine.

The license is initially for 10 years and includes up-front fees and an ongoing royalty on product sales. The genetically engineered cell lines are based on a new technology invented by Wang and his associates two years ago.

Human isogenic cell models known as cell lines and sometimes referred to as "patients-in-a-test-tube" accurately mimic disease-causing mutations, enabling researchers to better understand how cancer manifests itself in patients and to identify the effect of drug therapies and various outcomes.

"These cell lines provide unique tools for drug discovery, because they are cells that best represent human cancers. Further research based on these cells may lead to development of new cancer therapies," Wang said.

The lines will be added to Horizon Discovery's rapidly expanding library of X-MANTM (gene X- Mutant And Normal) cell models, which are used to successfully predict which patient groups will respond to currently available and future drug treatments. Research involving Horizon Discovery's proprietary rAAV GENESIS gene-editing platform seeks to enhance drug development, leading to personalized cancer therapies.

Chris Torrance, Horizon Discovery's co-founder and chief scientific officer, said that the cell lines will help researchers decipher how disease-associated genes work and "will open up new routes to develop novel targeted therapies."

"In partnering with Horizon, we gain a tremendous opportunity to bring these unique cancer cell lines to the market," said Stacy Fening, licensing associate for life sciences in Case Western Reserve's Technology Transfer Office. "Commercial deployment of these cell lines allows them to be used to their full potential to advance academic and pharmaceutical research in the cancer field."

Horizon Discovery Executive Chairman Darrin M. Disley said he is delighted that the company is now able to provide a commercial outlet for the research at Case Western Reserve's School of Medicine.

Disley said the freshly licensed panel of cell lines "will enable our customers to better understand the endogenous proteins that are activated/expressed when a human cell picks up the mutations implicated in the onset and progression of human cancers."


Contact: Marv Kropko
Case Western Reserve University

Related biology news :

1. Metabolism models may explain why Alzheimers disease kills some neuron types first
2. Study improves accuracy of models for predicting ozone levels in urban areas
3. Scientists create 3-D models of whole mouse organs
4. Study paves way for new biofuels models, technologies
5. Species distribution models can exaggerate differences in environmental requirements
6. Biochemist researching computer models of protein structure that help high school, college students
7. Animal models that help translate regenerative therapies from bench to bedside
8. Computer models suggest vaccination or culling best to prevent foot-and-mouth disease
9. Small molecules found to protect cells in multiple models of Parkinsons disease
10. Species distribution models are of only limited value for predicting future mammal distributions
11. Caltech researchers show efficacy of gene therapy in mouse models of Huntingtons disease
Post Your Comments:
(Date:5/12/2016)... 2016 , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: ) ... their customers enhanced security to access and transact ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology: